Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.52 |
| ▸ | ACACA | Q13085 | 5/20 | 0.47 |
| ▸ | ACACB | O00763 | 4/20 | 0.46 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | UTRN | P46939 | 1/20 | 0.42 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055876 | 0.90 | VSIR (0.54) | GPR119ACACAACACBVSIRACHE | |
| SCHEMBL4051596 | 0.83 | GPR119 (0.55) | GPR119VSIRF2RL3 | |
| SCHEMBL4054733 | 0.83 | GPR119 (0.43) | GPR119VSIRUTRNF2RL3 | |
| SCHEMBL4053094 | 0.83 | FFAR1 (0.51) | GPR119VSIRUTRN | |
| SCHEMBL4231839 | 0.82 | GPR119 (0.46) | GPR119VSIRUTRNF2RL3 | |
| SCHEMBL4054837 | 0.82 | UTRN (0.46) | GPR119VSIRUTRN | |
| SCHEMBL4057690 | 0.80 | GPR119 (0.55) | GPR119ACACAACACBVSIR | |
| SCHEMBL4050525 | 0.80 | GPR119 (0.51) | GPR119VSIRUTRN | |
| SCHEMBL4058058 | 0.80 | CEPT1 (0.50) | GPR119VSIRUTRN | |
| SCHEMBL4061879 | 0.79 | GPR119 (0.56) | GPR119ACACAACACBF2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | GPR119 1677/4885ACACA 3208/4885ACACB 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.